← boardnext 2026-12-31next 2027-12-01next 2028-12next 2028-12-30
RVMD
Revolution Medicines, Inc.distress 1/10 · well-funded / low risk$189.37+3%today-2% from 52w high
Oncology 1
Lead: PDAC · target RAS
Revenue
pre-revenue
Liquidity
$1908M
Runway
1.8 yrs
Shares 1y
+14%
Price & events
+59.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
+3.5%
1D
+5.7%
1W
+11.7%
1M
+40.8%
3M
+61.0%
6M
+404.6%
1Y
+304.9%
2Y
+554.4%
5Y
+399.3%
All
Overview
- Market Cap
- $40.26B
- Volume
- 205.91K
- 52 Week Range
- $34.70 – $193
- Total Shares
- 212.60M
- Float Shares
- 194.11M
- Short %
- 6.40%
- % Held by Insiders
- 1.90%
- % Held by Institutions
- 95.97%
- RVOL
- 0.07x
- Beta
- 1.38
Pipeline stages · 4 programs
RMC-5127, daraxonrasib, cetuximab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
daraxonrasib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Elironrasib, Daraxonrasib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Zoldonrasib, Oxaliplatin, Leucovorin (Calcium Folinate)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 13 trials · 12 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12-31 Estimated 50% readout ~2027-01-30 | Phase 1 | RMC-9805, RMC-6236 | Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors | — | recruiting |
| 2027-03-31 Estimated 50% readout ~2027-04-30 | Phase 1 | RMC-6291 | Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor | — | active not recruiting |
| 2027-05-15 Estimated 50% readout ~2027-06-29 | Phase 1/2 | RMC-6236, mFOLFOX6 regimen, bevacizumab | Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma | — | recruiting |
| 2027-05-31 Estimated 50% readout ~2027-07-15 | Phase 1/2 | RMC-6236 | Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors | — | recruiting |
| 2027-06 Estimated 50% readout ~2027-07-16 | Phase 1/2 | RMC-6291, RMC-6236, Pembrolizumab | Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer, RAS G12D-mutated NSCLC | — | recruiting |
Show all 13 trials · 8 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-12-01 Estimated 50% readout ~2028-02-14 | Phase 3 | daraxonrasib, docetaxel | NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma), NSCLC (Advanced Non-small Cell Lung Cancer) | — | recruiting |
| 2028-04 Estimated 50% readout ~2028-05-01 | Phase 1 | RMC-5127, daraxonrasib, cetuximab | Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), PDAC, CRC, NSCLC, Pancreatic Cancer, Lung Cancer (NSCLC), Advanced Solid Tumors | — | recruiting |
| 2028-06 Estimated 50% readout ~2028-08-15 | Phase 3 | daraxonrasib, gemcitabine, nab-paclitaxel | Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma | — | recruiting |
| 2028-12 Estimated 50% readout ~2029-01-15 | Phase 1/2 | Elironrasib, Daraxonrasib | Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma | — | recruiting |
| 2028-12-30 Estimated 50% readout ~2029-03-15 | Phase 3 | Zoldonrasib, Oxaliplatin, Leucovorin (Calcium Folinate) | Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma | — | recruiting |
| 2029-05 Estimated 50% readout ~2029-06-15 | Phase 1/2 | Daraxonrasib, Elironrasib, Zoldonrasib | Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC, Colorectal Cancer (CRC), CRC | — | recruiting |
| 2029-05-10 Estimated 50% readout ~2029-07-24 | Phase 3 | daraxonrasib | Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Resected Pancreatic Adenocarcinoma | — | recruiting |
| 2026-06 | Phase 3 | RMC-6236, Gemcitabine, nab-paclitaxel | Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma | 500 | active not recruiting |
Catalyst news & presentations · 6
- prior to January 1, 2030Guided 40%trial initiationsecondaryPhase 3RMC-6236 · Potential Phase 3 trial for first-line PDACSEC 8-K
- prior to January 1, 2028Guided 40%readoutPhase 3RMC-6236 · Positive data readout from RASolute 302 Phase 3 trial triggering Tranche 2 paymentSEC 8-K
- prior to January 1, 2028Guided 40%regulatory submissionFiled (NDA/BLA)RMC-6236 · FDA submission after positive RASolute 302 readoutSEC 8-K
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
- 2025-10-16fda agreementdaraxonrasib · Granted non-transferrable voucher under National Priority Voucher pilot program.SEC 8-K
- 2025-06-23partnershipEntered into royalty purchase agreement with Royalty Pharma for up to $1.25B in additional paymentsSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 212,596,462 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $201 (+6% upside) · 22 analysts
- 2026-07-20NeedhamBuy
- 2026-07-09GuggenheimBuy
- 2026-07-06HC Wainwright & Co.Buy
- 2026-07-06MizuhoOutperform
- 2026-07-02WedbushOutperform
- 2026-06-30Truist SecuritiesBuy
Competitors — RAS
- none identified
Recent news
- 2026-07-22Revolution Medicines (RVMD) Sees FDA Acceptance for Daraxonrasib Review - GuruFocus
- 2026-07-22Revolution Medicines’ New Drug Application for Daraxonrasib - GlobeNewswire
- 2026-07-22Revolution Medicines, Inc. (RVMD) Q3 2024 Earnings Report - Results, Call & Slides - TipRanks
- 2026-07-21RVMD Maintained by Needham -- Price Target Raised to $236 - GuruFocus
- 2026-07-20Revolution Medicines, Inc. (RVMD) Stock Analysis: Why Analysts Are Bullish on This $39.58 Billion Biotech Innovator - DirectorsTalk Interviews
- 2026-07-13Revolution Medicines, Inc. (RVMD) Stock Analysis: A Biotech Titan with a Promising 7.17% Upside - DirectorsTalk Interviews
- 2026-07-12‘Pharma Bro’ Martin Shkreli Defends Revolution Medicines’ Pancreatic Cancer Study Data: ‘Progress Compounds’ - Stocktwits
- 2026-07-08Revolution Medicines (RVMD) Wins Faster Reviews, Is The Valuation Already Too Rich? - simplywall.st
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.